The VA's newly launched psilocybin PTSD/TRD trials will register primary endpoints framed as safety/feasibility, not efficacy, on ClinicalTrials.gov by Q4 2026.

The VA (the US government's veterans healthcare system) is running studies on psilocybin — the active compound in magic mushrooms — for veterans with PTSD and stubborn depression. These trials will officially measure whether the treatment is safe and practical to run, not whether it actually works. That's a deliberate choice: asking 'does it work?' too early invites regulatory and political backlash the VA isn't ready to handle.

Government-sponsored psychedelic trials default to conservative endpoints to survive scrutiny. Efficacy claims invite regulatory exposure the VA won't risk this early.